NASDAQ:CNTB Connect Biopharma Q1 2025 Earnings Report $1.81 -0.05 (-2.69%) As of 11:23 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Connect Biopharma EPS ResultsActual EPS-$0.19Consensus EPS -$0.26Beat/MissBeat by +$0.07One Year Ago EPSN/AConnect Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConnect Biopharma Announcement DetailsQuarterQ1 2025Date5/15/2025TimeBefore Market OpensConference Call DateThursday, May 15, 2025Conference Call Time9:00AM ETUpcoming EarningsConnect Biopharma's H1 2025 earnings is scheduled for Friday, September 5, 2025, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Connect Biopharma Earnings HeadlinesConnect Biopharma to Participate in the BTIG Virtual Biotechnology Conference3 hours ago | globenewswire.comLisa Peraza - CNTB | Connect Biopharma Holdings Ltd. ADR - Wall Street ...July 17 at 9:03 PM | wsj.comElon’s Party Just Hit the IRS Where It HurtsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regain control, one overlooked IRS “backdoor” still allows retirement savers to protect their wealth — penalty-free and tax-free. A free 2025 guide reveals how to use it before it’s too late.July 18 at 2:00 AM | Priority Gold (Ad)Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 17 at 9:00 AM | globenewswire.comConnect Biopharma’s Exclusive Licensee in China, Simcere ...July 11, 2025 | morningstar.comMCNTB Stock Quote Price and Forecast | CNN - CNN InternationalJuly 11, 2025 | edition.cnn.comSee More Connect Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Connect Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Connect Biopharma and other key companies, straight to your email. Email Address About Connect BiopharmaConnect Biopharma (NASDAQ:CNTB) Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of monoclonal antibody and small-molecule therapies for immune-mediated diseases. Since its inception, the company has pursued a precision immunology approach, applying advanced screening and antibody engineering technologies to identify targets implicated in inflammatory pathways. Connect Biopharma’s research platform is designed to accelerate the transition of promising candidates from laboratory to clinical testing. The company’s lead programs include CBP-201, a fully human monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), currently in Phase II trials for ulcerative colitis and psoriasis, and CBP-307, an oral sphingosine-1-phosphate receptor modulator in development for inflammatory bowel disease. Both candidates leverage proprietary binding and pharmacokinetic optimization to achieve sustained target engagement while minimizing off-target effects. These pipelines are supported by a robust preclinical portfolio aimed at additional cytokine and chemokine targets. Headquartered in Hong Kong with research facilities in Shanghai and clinical operations in the United States, Connect Biopharma conducts global studies spanning Asia, Europe and North America. The company maintains strategic partnerships with academic institutions and contract research organizations to advance its therapeutic candidates through regulatory milestones. Its network of external collaborators aids in biomarker development and patient stratification strategies to enhance trial efficiency. Connect Biopharma’s leadership team comprises seasoned executives and scientific founders with deep experience in immunology, biologics development and global clinical operations. Guided by its mission to bring transformative treatments to patients with chronic inflammatory disorders, the company continues to expand its portfolio and advance novel assets toward commercialization.Written by Jeffrey Neal JohnsonView Connect Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
